Terumo : Financial Results for the First Quarter of Fiscal Year Ending March 31, 2024 (FY2023)
August 09, 2023 at 02:39 am EDT
Share
Financial Results for the First Quarter of Fiscal Year Ending March 31, 2024 (FY2023)
August 9, 2023
Naoki Muto
Chief Accounting and Financial Officer Terumo Corporation
Forward-Looking Statements and Use of Document
Among the information that Terumo discloses, the forward-looking statements including financial projections are based upon our assumptions using information available to us at the time and are not intended to be guarantees of future events or performance. Accordingly, it should be noted that actual results may differ from those forecasts or projections due to various factors. Factors affecting to actual results include, but are not limited to, changes in economic conditions surrounding Terumo, fluctuations of foreign exchange rates, and state of competition. Information about products (including products currently in development) which is included in this material is not intended to constitute an advertisement or medical advice.
Terumo Corporation published this content on 09 August 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 09 August 2023 06:38:02 UTC.
Terumo Corporation specializes in the design, manufacturing and marketing of medical products and equipments. Net sales break down by family of products as follows:
- cardiac surgery devices (53.5%);
- medical products for hospitals (28.6%): medical devices, nutritional additives, oxygen, medical measuring devices (thermometers, tensiometers, glucometers, etc.), etc.;
- sanguine transfusion equipments (17.9%).
Net sales break down geographically as follows: Japan (32.9%), America (29.5%), Europe (19.6%), China (7.4%) and other (10.6%).
TERUMO CORPORATION 
